Cost-effectiveness of malaria preventive treatment for HIV-infected pregnant women in sub-Saharan Africa

Malaria Journal

Table 3 Base case results

Country and strategy	Costs per 10,000 women (USD)	DALYs per 10,000 women	Incremental cost	Incremental DALYs averted	ICER
Ghana
2-IPT Low^a	359,992	12,055
3-IPT Low	360,340	11,912	348	143	Dominated^b
3-IPT High	361,594	11,434	1602	621	Dominated
CTX	361,009	9312	1017	2743	$0.37
Malawi
2-IPT Low^a	393,772	14,671
3-IPT Low	394,744	14,563	972	108	Dominated^b
3-IPT High	399,172	12,382	5400	2289	Dominated
CTX	396,580	11,317	2808	3354	$0.84
Kenya
2-IPT Low^a	383,217	7000
3-IPT Low	384,314	6934	1097	66	Dominated^b
3-IPT High	388,568	6183	5351	817	Dominated
CTX	386,518	5339	3301	1661	$1.99
Mozambique
2-IPT Low^a	406,628	16,424
3-IPT Low	409,130	16,022	2502	402	Dominated
3-IPT High	409,367	15,997	2739	427	Dominated
CTX	404,816	15,240	−1812	1184	Cost-saving
Tanzania
2-IPT Low^a	367,892	4364
3-IPT Low	370,519	4327	2627	37	Dominated^b
3-IPT High	371,468	4231	3576	133	Dominated
CTX	371,154	3516	3262	848	$3.85

CTX cotrimoxazole, DALY disability-adjusted life year, ICER incremental cost-effectiveness ratio (cost per DALY averted) compared to the strategy in the row above, IPT intermittent preventive treatment with sulfadoxine–pyrimethamine
^aReference Strategy
^bDominated by extended dominance: a linear combination of two other strategies yields greater benefit at equal cost

ISSN: 1475-2875